Rosacea is a chronic inflammatory vascular condition affecting 16 million Americans
Rosacea is not blushing or sensitive skin. The condition involves vascular instability (blood vessels that dilate and fail to constrict), innate immune system dysfunction (cathelicidin overproduction), and Demodex folliculorum mite overgrowth (density 6x higher than healthy skin). Effective management requires reducing inflammation, controlling Demodex populations, and supporting barrier function without triggering vascular reactivity.How rosacea works
The four subtypes
Erythematotelangiectatic (ETR): Persistent central facial redness, visible blood vessels, flushing episodes lasting 10+ minutes. The most common subtype. Triggered by temperature changes, alcohol, spicy food, and UV exposure. Papulopustular: Red bumps (papules) and pus-filled bumps (pustules) on a background of facial redness. Often misdiagnosed as adult acne. Distinguished from acne by absence of comedones (blackheads/whiteheads) and by central facial distribution. Phymatous: Skin thickening, particularly on the nose (rhinophyma). Sebaceous gland hypertrophy produces bumpy, enlarged tissue. Most common in men. Develops over years of uncontrolled rosacea. Ocular: Eye involvement — burning, stinging, dryness, foreign body sensation, recurrent styes. Affects 50% of rosacea patients. Often precedes skin symptoms by months or years.The cathelicidin pathway
Healthy skin produces cathelicidin antimicrobial peptides (LL-37) in controlled amounts for microbial defense. Rosacea skin overproduces cathelicidin by 10-100x. Kallikrein 5 (KLK5), a protease enzyme, cleaves cathelicidin into pro-inflammatory fragments that trigger vascular dilation, recruit immune cells, and stimulate angiogenesis (new blood vessel formation). This pathway explains why rosacea skin is simultaneously inflamed and prone to new visible vessels.Demodex folliculorum involvement
Demodex mites are microscopic arachnids living in hair follicles. Healthy skin hosts 0.7 mites per square centimeter. Rosacea skin hosts 5-6 mites per square centimeter — a 6-8x density increase. Demodex mites carry Bacillus oleronius bacteria in their gut, which triggers immune response upon mite death. The mite lifecycle (14-16 days) creates periodic inflammatory waves as generations die and release bacterial antigens.Vascular instability
Rosacea involves structural changes to facial blood vessels: increased VEGF (vascular endothelial growth factor) production stimulates angiogenesis, creating new fragile capillaries. Existing vessels develop impaired vasoconstriction — they dilate in response to triggers but fail to constrict back to baseline. Over time, persistent dilation becomes fixed as vessel walls remodel.Why mainstream rosacea treatments fall short
Metronidazole (MetroGel, MetroCream)
What it does: Reduces papulopustular rosacea inflammation. Mechanism not fully understood — likely anti-inflammatory rather than antimicrobial at rosacea concentrations. Limitations: Does not address vascular instability. Does not reduce Demodex density effectively. Requires 4-8 weeks for visible improvement. Application site irritation in 15-20% of users. Must be used indefinitely — rosacea returns upon discontinuation.Azelaic acid (Finacea 15%)
What it does: Anti-inflammatory, reduces papulopustular lesions. Normalizes keratinization. Limitations: Burning and stinging in 30% of users — problematic for a condition characterized by skin reactivity. Does not address vascular component. Does not reduce Demodex populations. Slow onset (8-12 weeks).Brimonidine (Rhofade/Mirvaso)
What it does: Alpha-2 adrenergic agonist that constricts blood vessels. Reduces facial redness within 30 minutes. Limitations: Rebound redness — vessels dilate worse than baseline when the medication wears off (8-12 hours). Documented “rebound flare” pattern where patients become dependent on twice-daily application to avoid worsening. Does not address inflammation, Demodex, or cathelicidin overproduction. Treats the visible symptom only.Oral antibiotics (doxycycline, minocycline)
What they do: Anti-inflammatory at sub-antimicrobial doses. Reduce papulopustular lesions. Limitations: Systemic side effects (GI disruption, photosensitivity, yeast infections). Long-term use contributes to antibiotic resistance. Does not address vascular instability. Rosacea returns upon discontinuation in most patients. Not appropriate for indefinite use despite the chronic nature of the condition.Common rosacea triggers
| Category | Specific triggers | Mechanism |
|---|---|---|
| Temperature | Hot drinks, hot showers, cold wind | Direct vasodilation (heat) or vasoconstriction-then-dilation rebound (cold) |
| Alcohol | Red wine, spirits, beer | Histamine release + acetaldehyde-induced vasodilation |
| UV radiation | Sun exposure without protection | VEGF upregulation + cathelicidin activation + direct vascular damage |
| Spicy food | Capsaicin-containing foods | TRPV1 receptor activation on sensory nerves triggers neurogenic vasodilation |
| Stress | Emotional or physical stress | Cortisol and norepinephrine alter vascular tone + increase inflammation |
| Skincare ingredients | Alcohol, fragrance, SLS, retinoids | Barrier disruption increases vascular reactivity + direct irritation |
What Era Organics offers for rosacea
Era Organics addresses rosacea through antimicrobial control (Demodex and bacterial management), anti-inflammatory activity (reducing cathelicidin cascade), and gentle barrier support (without vascular triggers).The rosacea product stack
| Product | Primary mechanism | Role in rosacea management |
|---|---|---|
| HOCl Spray | Antimicrobial + anti-inflammatory | Reduces Demodex-associated bacteria, calms inflammation without irritation |
| Face Moisturizer | Barrier support, no fragrance, no irritants | Maintains barrier integrity without triggering vascular reactivity |
| Face Wash Sensitive | Gentle cleansing, no SLS | Removes debris without barrier disruption or flushing |
The protocol (daily management)
- Cleanse with Face Wash Sensitive — lukewarm water only, no hot water (heat triggers flushing)
- Apply HOCl Spray to entire face — antimicrobial activity reduces Demodex bacterial load
- Wait 30 seconds for HOCl to dry
- Apply Face Moisturizer — barrier support without fragrance, alcohol, or vasodilating ingredients
The protocol (flare response)
- Identify and eliminate the trigger immediately
- HOCl Spray applied 3-4x daily to reduce inflammatory bacterial load
- Cool (not cold) compress for 5 minutes to reduce acute vasodilation
- Face Moisturizer to prevent barrier compromise during the inflammatory episode
- Avoid all other topical products until the flare subsides
Era Organics vs. mainstream rosacea treatments
| Factor | Era Organics (HOCl + Moisturizer) | Metronidazole | Azelaic acid 15% | Brimonidine |
|---|---|---|---|---|
| Addresses inflammation | Yes (HOCl anti-inflammatory) | Yes | Yes | No (vasoconstrictor only) |
| Addresses Demodex | Yes (HOCl antimicrobial) | Minimal | No | No |
| Addresses barrier | Yes (Face Moisturizer) | No | No | No |
| Rebound risk | None | None | None | High (documented rebound redness) |
| Irritation potential | Minimal (HOCl is endogenous) | 15-20% irritation | 30% burning/stinging | Contact dermatitis reported |
| Onset of benefit | Days (antimicrobial) | 4-8 weeks | 8-12 weeks | 30 minutes (temporary) |
| Fragrance-free | Yes | Varies by formulation | Yes | Yes |
| Prescription required | No | Yes | Yes | Yes |